醒脑注射液在脑梗死患者中的应用及安全性研究

doi:10.3969/j.issn.1006-6233.2017.08.020

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1363 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To analyze the effect and safety of Xingnaojing injection in patients with cerebral infarction. Methods: 100 patients with acute cerebral infarction from December 2016 to June 2017 were randomly divided into observation group and control group according to the number table method. The control group was treated with conventional western medicine. The observation group was treated with Xingnaojing injection on the basis of the control group. The clinical efficacy of the two groups was observed and the changes of the neurological deficits (NIHSS score) and the daily life ability score (Barthel index) were compared before and after treatment for two months before treatment, and the two groups Patient during the treatment of adverse reactions. Results: The clinical efficacy of the observation group and the control group was 92.0% and 82.0%, the observation group was better than the control group (P <0.05); before and after treatment NIHSS score and Barthel index and after treatment, were statistically significant (P <0.05). However, the improvement rate of the observation group was significantly higher than that of the control group (P <0.05). No serious adverse reactions occurred during the treatment period, which indicated that the brain was safe. Conclusion: Xingnaojing injection has a good effect in patients with cerebral infarction, which can effectively improve the neurological deficits of patients and improve the daily life ability of patients. It can effectively improve the quality of life of patients and has few adverse reactions. Promote the use of clinical.

Key words： Xingnaojing injection Cerebral infarction Clinical efficacy Safety

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WU Wanyu
	LIAO Jun
	HUANG Jie
	et al

Cite this article:

WU Wanyu,LIAO Jun,HUANG Jie, et al. Application of Xingnaojing Injection in Patients with Cerebral Infarction and Its Safety[J]. 河北医学, 2017, 23(8): 1304-1306.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2017.08.020 OR http://www.hbyxzzs.cn/EN/Y2017/V23/I8/1304

[1] 李乙根.醒脑静注射液治疗脑梗塞急性期临床疗效观察[J].吉林中医药,2015,29(7):582~583.
[2] 许风雷,高丽霞,吴泰相等.醒脑静注射液治疗脑梗塞临床疗效及安全性随机对照试验的系统评价[J].中国循证医学杂志,2015,5(7):549~554.
[3] 雷奕祺,袁明远,史东葵等.醒脑静注射液与安宫牛黄丸治疗脑梗塞急性期临床对照研究[J].中国中医急症,2015,11(5):359~360.
[4] 雷奕祺,洪少勇,史东葵等.醒脑静注射液与安宫牛黄丸对脑梗死急性期患者神经功能缺损程度的影响[J].中国临床康复,2015,9(13):246~247.
[5] 周彬,李劼,娄刚等.醒脑静联合丹参注射液治疗急性脑梗塞45例临床观察[J].中国中医药科技,2016,23(5):563~564.
[6] 张松礼,陈诚.醒脑静注射液治疗脑梗塞临床疗效探讨[J].齐齐哈尔医学院学报,2015,34(24):3643~3644.
[7] 张磊.早期针灸和联合醒脑静注射液干预对大面积脑梗塞昏迷患者临床疗效分析[J].中医临床研究,2015,7(19):37~38.
[8] 黄晓丽,张晓艳,张俊等.醒脑静注射液对老年腔隙脑梗塞患者生存质量的影响[J].华西医学,2015,20(3):486~487.
[9] 李昶,茹雪莹,吴泰相等.醒脑静注射液治疗急性脑梗死随机对照试验的系统评价[J].临床荟萃,2015,28(9):1006~1013.
[10] 饶春光.醒脑静注射液联合依达拉奉治疗急性脑梗塞90例[J].陕西中医,2014,29(10):1304~1305.
[11] 郭笃光,于艳红.脑苷肌肽联合醒脑静注射液治疗脑梗塞的临床研究[J].中国中医药咨讯,2014,04(1):126~127.
[12] Lee J H,Choi H C,Kim C,et al.Fulminant cerebral infarction of anterior and posterior cerebral circulation after ascending type of facial necrotizing fasciitis[J].Journal of stroke and cerebrovascular diseases: The official journal of National Stroke Association,2014,23(1):173~175.
[13] Chu H X,Kim H A,Lee S,et al.Immune cell infiltration in malignant middle cerebral artery infarction: Comparison with transient cerebral ischemia[J].Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism,2014,34(3):450~459.
[14] Saleh A,Wiedermann D,Schroeter M.etc.Central nervous system inflammatory response after cerebral infarction as detected by magnetic resonance imaging[J].NMR in biomedicine,2014,17(4):163~169.
[15] Amorim R L,De Andrade,et al.Improved hemodynamic parameters in middle cerebral artery infarction after decompressive craniectomy[J].Stroke: A Journal of Cerebral Circulation,2014,45(5):1375~1380.